Mahgoub E S
Bull World Health Organ. 1976;54(3):303-10.
A number of drugs and drug combinations were tested both in vitro and in vivo against pathogens causing actinomycetoma and maduromycetoma. Of 144 patients with actinomycetoma treated, 63.2% were cured, 21.5% showed great improvement in their condition, and 11.1% showed some improvement. Treatment was successful even when there was advanced bone involvement. The most effective treatments involved dapsone plus streptomycin sulfate or sulfamethoxazole-trimethoprim plus streptomycin. Sulfadoxine-pyrimethamine plus streptomycin or rifampicin plus streptomycin also gave good results. Griseofulvin plus penicillin showed some promise in the management of maduromycetoma caused by Madurella mycetomi but at the present time this should be used only as an adjunct to surgery. All mycetoma patients undergoing drug therapy should be carefully monitored and treatment should be temporarily suspended if anaemia or leucopenia develop.
对多种药物及药物组合进行了体外和体内测试，以对抗引起放线菌性足菌肿和马杜拉菌性足菌肿的病原体。在接受治疗的144例放线菌性足菌肿患者中，63.2%治愈，21.5%病情显著改善，11.1%有一定改善。即使存在晚期骨受累，治疗仍取得成功。最有效的治疗方法包括氨苯砜加硫酸链霉素或磺胺甲恶唑-甲氧苄啶加链霉素。磺胺多辛-乙胺嘧啶加链霉素或利福平加链霉素也取得了良好效果。灰黄霉素加青霉素在治疗由马杜拉菌引起的马杜拉菌性足菌肿方面显示出一定前景，但目前仅应作为手术的辅助手段使用。所有接受药物治疗的足菌肿患者均应仔细监测，如出现贫血或白细胞减少，应暂停治疗。
